In this study, using LK79 – a SCLC cell line – as a target, which produces high amounts of CCL2 (Table 2 and Fig. 1A), and effector CTLs double-transfected to express WT1-specific TCR and CCR2, we successfully demonstrated both the feasibility and advantages of targeting an optimal chemokine produced by tumor cells, to achieve successful adoptive therapy. The gene discussed is CCL2; the disease is neoplasm.